| SC 13G/A | 2024-02-14 | Avoro Capital Advisors LLC | Mersana Therapeutics, Inc. | 0 | 0.0% | EDGAR |
| SC 13G/A | 2024-02-14 | ORBIMED ADVISORS LLC | Mersana Therapeutics, Inc. | 0 | 0.0% | EDGAR |
| SC 13G/A | 2024-02-14 | Venrock Healthcare Capital Partners III, L.P. | Mersana Therapeutics, Inc. | 11,328,000 | 9.4% | EDGAR |
| SC 13G | 2024-02-14 | BALYASNY ASSET MANAGEMENT L.P. | Mersana Therapeutics, Inc. | 9,698,147 | 8.0% | EDGAR |
| SC 13G | 2024-02-14 | SILVERARC CAPITAL MANAGEMENT, LLC | Mersana Therapeutics, Inc. | 6,420,136 | 5.3% | EDGAR |
| SC 13G | 2024-02-13 | VANGUARD GROUP INC | Mersana Therapeutics, Inc. | 6,237,588 | 5.2% | EDGAR |
| SC 13G/A | 2024-01-29 | BlackRock Inc. | Mersana Therapeutics, Inc. | 7,844,282 | 6.5% | EDGAR |
| SC 13G/A | 2024-01-22 | STATE STREET CORP | Mersana Therapeutics, Inc. | - | 1.9% | EDGAR |
| SC 13G | 2023-08-07 | Venrock Healthcare Capital Partners III, L.P. | Mersana Therapeutics, Inc. | 9,678,000 | 8.5% | EDGAR |
| SC 13G | 2023-07-27 | EcoR1 Capital, LLC | Mersana Therapeutics, Inc. | 19,364,688 | 16.9% | EDGAR |
| SC 13G/A | 2023-02-14 | Avoro Capital Advisors LLC | Mersana Therapeutics, Inc. | 7,550,000 | 7.6% | EDGAR |
| SC 13G/A | 2023-02-14 | Rho Ventures V, L.P. | Mersana Therapeutics, Inc. | 0 | 0.0% | EDGAR |
| SC 13G/A | 2023-02-14 | BB BIOTECH AG | Mersana Therapeutics, Inc. | 4,066,200 | 4.1% | EDGAR |
| SC 13G | 2023-02-14 | ORBIMED ADVISORS LLC | Mersana Therapeutics, Inc. | 7,082,837 | 7.1% | EDGAR |
| SC 13G/A | 2023-02-09 | VANGUARD GROUP INC | Mersana Therapeutics, Inc. | 4,449,040 | 4.5% | EDGAR |
| SC 13G/A | 2023-02-06 | WELLINGTON MANAGEMENT GROUP LLP | Mersana Therapeutics, Inc. | 0 | 0.0% | EDGAR |
| SC 13G/A | 2023-02-03 | STATE STREET CORP | Mersana Therapeutics, Inc. | - | 5.9% | EDGAR |
| SC 13G/A | 2023-01-31 | BlackRock Inc. | Mersana Therapeutics, Inc. | 7,491,929 | 7.5% | EDGAR |
| SC 13G/A | 2023-01-19 | MILLENNIUM MANAGEMENT LLC | Mersana Therapeutics, Inc. | 3,663,527 | 3.7% | EDGAR |
| SC 13D/A | 2022-05-11 | Bain Capital Life Sciences Fund II, L.P. | Mersana Therapeutics, Inc. | 3,294,423 | 3.4% | EDGAR |